In order to investigate the role of CHD2 haploinsufficiency in neurodevelopmental disorders, we describe the first series of patients with deletions affecting CHD2 from among a cohort of 42,313 patients broadly ascertained by clinical genetics laboratories to have developmental delay, intellectual disability, multiple congenital anomalies and/or ASD. This evidence concerns the gene CHD2 and Global developmental delay.